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Abstract
Non-compliance with established medical treatment guidelines can have dire consequences for public health
and economic well-being. Based on the Demographic and Health Surveys, we examine malaria treatment
practices of various health-care providers in sub-Saharan Africa, where more than 90% of malaria-induced
deaths occur. We estimate each provider’s likelihood (i) to comply with guidelines to administer (effective)
antimalarial drugs and (ii) to relieve children of fever—a symptom of malaria—after having had a fever
episode within the previous two weeks. Our results indicate that, relative to self medication, seeking treatment
at most providers is positively associated with taking an antimalarial drug and negatively associated with using
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Biting back at malaria: Assessing health-service providers’ 
compliance with treatment guidelines* 





 Non-compliance with established medical treatment guidelines can have dire 
consequences for public health and economic well-being. Based on the Demographic 
and Health Surveys, we examine malaria-treatment practices of various health-care 
providers in sub-Saharan Africa, where more than 90 percent of malaria-induced 
deaths occur. We estimate each provider’s likelihood (a) to comply with guidelines to 
administer (effective) antimalarial drugs and (b) to relieve children of fever—a 
symptom of malaria—after having had a fever episode within the last two weeks. Our 
results indicate that, relative to self-medication, seeking treatment at most providers is 
positively associated with taking an antimalarial drug and negatively associated with 
using only ineffective chloroquine. Non-traditional healers are also associated with 
fever relief. 
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Evidence-based treatment guidelines for diseases are regularly provided at the national and 
international levels. At the national level, these guidelines are issued either by the Ministry or 
Department of Health or by the professional regulatory associations; multilateral bodies, such as the 
World Health Organization (WHO), also prescribe how diseases should be treated. These guidelines are 
designed to improve health care and outcomes and to lower the cost of service provision. Deviations 
from the prescribed treatment protocol could result in ineffective and inefficient treatment. For 
communicable diseases, insufficient compliance will likely contribute to the spread of drug-resistant 
mutations of an infectious microorganism. As such, compliance with mandated guidelines is one 
indicator for the quality of health-service provision (Hesdorffer et al., 2002; Karbach et al., 2011; Sekhon 
et al., 2013). 
 The present paper is concerned with the compliance of health-service providers with 
international and national treatment guidelines for uncomplicated malaria.1 While these guidelines 
have rightfully changed over time in response to new evidence, declining prevalence, and the increasing 
availability of rapid diagnostic tests (RDT), our study time frame is primarily the period during which 
presumptive treatment of childhood malaria was the prescribed protocol. Under such a regime, 
antimalarial drugs should be administered to children if they present with fever even without a clinical 
confirmation of malaria. The rationale behind such a regime in regions like sub-Saharan Africa is that 
malaria is endemic to the area, with transmission rates that are quite high. This implies that the most 
likely underlying cause of a fever episode in children is malaria (Cohen et al., 2015), which should be 
treated immediately to improve the likelihood of being cured. Current WHO guidelines (2010) 
recommend “test and treat” (i.e., confirm the presence of the malaria parasite in a febrile child), but this 
is only possible where RDT kits are available or where access to trained personnel can lead to a 
confirmation. 
                                                        
1 “A patient who presents with symptoms of malaria and a positive parasitological test…but with no features of 




 In our study, we analyze the differences in febrile-children-treatment practices between self-
treatment, traditional healers, private health-care providers, and the public sector in western sub-
Saharan Africa. We specifically assess the treatment provided to children below five years old who had 
fever within the last two weeks by comparing the use patterns of antimalarial drugs and fever-
abatement rates. We interpret the likelihood of taking effective antimalarial drugs for febrile children 
as a indicator of overall quality because such adherence to treatment guidelines is—in the words of an 
anonymous reviewer—“indicative of an understanding, appreciation, and commitment to evidence-
based medicine”. 
 We contribute to the emergent development-economics debate on the quality of medical care in 
two ways. First, we present a novel way to assess the overall quality of medical care. While actual 
compliance with prescribed treatment guidelines as an indicator of overall health-care quality is not 
novel per se (e.g., Nshakira et al., 2002; WHO, 2003; Tavrow, Shabahag, and Makama, 2003), we propose 
to leverage the use of standardized household survey data such as the Demographic and Health Surveys 
(DHS), which is available in over 90 countries, as opposed to conducting costly provider  interviews 
(e.g., Ebtong et al., 2012).2 For policymakers and practitioners in the field of development, our analysis 
can be seen as another useful way to assess the quality of health-services providers, one that is much 
cheaper than administering, for example, clinical vignettes. Second, we present further empirical 
evidence on the overall quality of health care in the developing world. Generally, more evidence is 
needed to uncover areas where health systems fail so that appropriate measures to strengthen the 
health system may be put in place (Berman and Bitran, 2011). 
 The rest of the paper is structured as follows. Section 2 provides a discussion of related research 
on treatment practices and describes how we advance the literature. Section 3 contextualizes the issue 
of malaria in sub-Saharan Africa as well as the treatment regimes that are currently in place. Section 4 
briefly describes the data and the study population while Section 5 presents the estimation approach 
                                                        
2 Alternative measures of quality thus far have been predominantly assessed based on input factors, such as the 
physical infrastructure and the stock of medical supplies (e.g., Collier et al., 2003). More recently, clinical vignettes 




and the results. Section 6 offers an a discussion of the the heterogeneity across countries and over time 
before finally concluding in Section 7. 
2. RELATED LITERATURE 
Our understanding of the treatment practices of health-care providers and treatment-seeking behavior 
of malaria-infected individuals is asymmetric. While our knowledge of the latter is informed by a large 
body of evidence in the medical and social sciences (see McCombie (1996), for example), how providers 
behave—especially their treatment practices—is insufficiently explored in the existing literature. 
Indeed, as Williams and Jones (2004, p. 511) point out, “little emphasis has been given to examining 
how providers prescribe antimalarials.” Quality differences between health-care providers presumably 
exist, but the magnitudes of these differences—to our knowledge—have not always been explored with 
methodological rigor. 
 A few studies on antimalarial drug provision of different health-care providers (e.g., Onwujekwe 
et al., 2009; Smith et al., 2010; Ebong et al., 2012) exist, but the evidence is restricted to single countries 
and—due to a regional focus within these countries—are usually not representative of the population. 
Thus, the external validity that arise out of these estimates is limited. We use the nationally-
representative Demographic and Health Surveys (DHS) for eight West African countries (Benin, Burkina 
Faso, Ghana, Guinea, Liberia, Mali, Niger, and Nigeria) which allow us to assess heterogeneity in febrile-
children-treatment practices across countries. 
 Some studies examine the compliance only of health professionals without comparing them to 
traditional healers (Ughasoro et al., 2013). This is a significant gap since evidence suggests that 
traditional healers may, under certain conditions, be able to provide better health services to their 
patients. Leonard (2003) shows that traditional healers could be better because of the nature of the 
contract between the service provider and the patient. These contracts are typically outcome-
contingent—that is, a traditional healer will not get paid unless the desired outcome (being cured) is 
achieved. Both the patient and the healer, therefore, will have an incentive to increase their effort to be 




cured. In this paper, we explicitly compare the outcomes achieved by the formal sector relative to those 
achieved both by self-medication and going to traditional healers. 
 Understanding these quality differences is important because “in sub-Saharan Africa, the 
pragmatic choice for prompt and effective treatment (especially for uncomplicated malaria) currently 
lies outside the formal health sector” (Williams and Jones, 2004, p. 514). Based on our dataset, the share 
of children undergoing self-medication is about a fifth of the population of febrile children. In Burkina 
Faso, for example, it is over 50 percent. Over 17 percent of febrile children in Benin go to a traditional 
healer. While these health-care providers may be prompt at delivering some type of medication, the 
effectiveness of these drugs is rightly questionable. The extent to which these providers comply with 
national and international treatment guidelines is an important measure to assess their quality. 
 To this end, we are the first who aim to extensively control for confounding factors, such as the 
educational background of the guardians. The guardian’s education, for example, is likely to be related 
to both health-care provider choice and knowledge of effective malaria treatments. Thus, we mitigate 
spurious correlations better than previous studies, which abstain from employing multivariate 
regressions and are based merely on regional samples within a country. We also assess whether there 
exists a socioeconomic gradient in the quality of malaria treatment across different providers. We 
further examine differences in treatment practices across countries and, hence, institutional settings. 
Similarly, we compare Ghana and Nigeria over two years to give an indication of how different policy 
implementations affect treatment practices. Although the countries we examine all belong to western 
sub-Saharan Africa, national health institutions could potentially be quite different between countries, 
and this should be taken into account in the analysis. 
3. BACKGROUND 
Malaria kills about 660,000 people each year. The majority of deaths (86 percent) occur in children 
below five years of age. Approximately 1,500 children die due to malaria every day. Most of them are 
located in sub-Saharan Africa, where the highest malaria-parasite prevalence rates are reported for 




preceived as unacceptable since malaria is considered as an entirely preventable and treatable disease. 
As a consequence, bilateral donors, the World Bank, and the Global Fund to Fight AIDS, Tuberculosis 
and Malaria have substantially increased malaria-control funding and provided technical assistance 
through the World Health Organization (WHO) and the Roll Back Malaria Partnership for years. In fact, 
international disbursements for malaria control rose from US$ 100 million in 2000 to US$ 1.71 billion 
in 2010, a 17-fold increase. 
 The principal vector for malaria is the female Anopheles mosquito which carries the malaria 
parasite, a Plasmodium protozoan. The five species that have been documented to cause malaria in 
humans are Plasmodium falciparum, P. vivax, P. malariae, P. ovale, and, rarely, P. knowlesi (WHO, 
2014a). The P. falciparum variant accounts for the majority of deaths due to malaria followed by 
P. vivax. The geographic region under study—western sub-Saharan Africa—is susceptible primarily to 
P. falciparum, since P. vivax does not commonly infect people who belong to the Duffy-negative blood 
group to which most people from West Africa belong (Ménard et al., 2010). There is grave concern 
worldwide with the spread of multi-drug-resistant P. falciparum and the insecticide-resistant mosquito 
vector since P. falciparum is also the most virulent strain. 
 Our study region is a hotbed for P. falciparum malaria. Based on information from the World 
Malaria Report 2014 (WHO, 2014b), about 128 million people were infected by P. falciparum in 2013. 
West Africa had the highest rates of infection for children aged 2–10 years. In 15 sub-Saharan countries, 
over a fifth of the children’s population is infected. Fortunately, the trend is declining: “Eight sub-
Saharan countries are estimated to have achieved declines of [over 75 percent], and 14 countries 
achieved declines of [over 50 percent] between 2000 and 2013” (WHO, 2014b, p. 35). 
 The treatment for uncomplicated malaria traditionally consisted of a regimen of chloroquine 
(CQ). However, resistance to CQ has been known since the 1950s. Almost the whole of tropical and sub-
tropical Africa shows an elevated level of CQ-resistant P. falciparum malaria (Figure 1). For a time, 
sulphadoxine-pyrimethamine (SP) replaced CQ as the first-line treatment regimen for uncomplicated 




 More recently, combination therapies are recommended to prevent the spread of multi-drug-
resistant parasites. Over the last few years, especially beginning in 2004, most African countries have 
transitioned to artemisinin-based combination therapies (ACTs), with South Africa beginning in 2001. 
Although Malawi was the first in this region to transition out of CQ in 1993 (CQ was replaced with SP as 
the first-line treatment), it was the last to adopt ACTs together with Botswana in 2007 (Flegg et al., 
2013). The sub-Saharan and West African countries included in this study have all adopted artemisinin-
based therapies in recent years. 
 The WHO (2006b) notes that artemisinin derivatives marketed in some countries are 
monotherapies. This practice, “if unabated, will promote development and spread of resistance and 
compromise the effectiveness of ACTs.” It is therefore important that health practitioners comply with 
the national guidelines that recommend combination therapies as the first-line treatment. First, it 
prevents the use of ineffective medicine, such as either CQ or SP; second, it prevents the emergence and 
spread of multi-drug-resistant parasites, against which the international community has not yet 
developed effective alternatives. 
 The current evidence shows that national and global efforts at encouraging ACTs are bearing 
fruit: the prevalence rate of P. falciparum in children aged 2–10 in sub-Saharan Africa has declined “from 
37% in the years 1985–1999 to 17% in 2000–2007” (D’Acremont et al., 2009). This fact, coupled with 
the increasing supply and decreasing cost of RDTs, have generated a debate about the usefulness of the 
presumptive treatment regime in P. falciparum-endemic countries. With the declining prevalence of the 
parasite, the risk of mistreatment or overtreatment with ACTs increases, which could have negative 
consequences in terms of its adoption. As Adhvaryu (2014) demonstrates using data from Tanzania, if 
ACTs are overprescribed, its widespread adoption may be impaired by the fact that some of its recipients 
may not even have malaria. In that case, ACTs may not do anything to cure the underlying true cause of 
the disease, prolonging the fever episode (or some other worse outcome). Patients may then conclude 




 Although the medical community is not unanimous, the WHO has already abandoned 
presumptive treatment in favor of a “test and treat” (and track) strategy: “In all settings, suspected 
malaria should be confirmed with a parasitological test.” (WHO, 2015, p. 29) As noted elsewhere, this is 
a remarkable departure from previous guidelines (Graz et al., 2011), which allowed for presumptive 
treatment especially in malaria-endemic areas with high transmission rates. The test-and-treat 
approach is meant to ensure that malaria drugs are only used in actual malaria cases. This change also 
reflects the fact that RDTs are now much more widely available.3 Fortunately, recent data show that 
diagnostic tests now exceed the number of ACTs distributed in the public sector (WHO, 2014b). Since 
not all presentations of fever are necessarily malaria, we expect that testing should always exceed 
treatment, so this is positive news. 
 The WHO recommendation of treating uncomplicated malaria with ACT as a first-line treatment 
for P. falciparum malaria has been widely adopted in the African region. Of the 44 countries where 
P. falciparum malaria is endemic, 43 have already adopted ACT (WHO, 2014b). All West African 
countries included in this study have adopted artemisinin-based combination therapies in recent years.
 Regarding adoption of the test-and-treat approach, “the WHO African Region has seen the 
largest increase in the proportion of suspected cases tested, from 47% in 2010—when WHO’s 
recommendation to test all suspected malaria cases was introduced—to 62% in 2013.” (WHO, 2014b, 
p. 20) 
 According to the latest WHO country profiles (WHO, 2014b), all countries in our paper have also 
at least nominally adopted the testing regime, with the earliest one being Liberia in 2005 and the latest 
one being Guinea in 2012. Previously, presumptive treatment was in place. Unfortunately, “nearly 40% 
of people with suspected malaria at public health facilities in Africa are not tested”,4 implying that there 
remains a significant divide between the international guidelines and national implementation. 
                                                        
3 “[RDTs] are now widely available and more than 319 million were purchased in 2013 compared to 46 million in 
2008,” according to a WHO news release available from http://goo.gl/DfdpJn. 




 While the proportion of children in sub-Saharan Africa receiving ACT for P. falciparum malaria 
has been increasing, it remains below 20 percent at least until 2013; in public health facilities, the 
proportion ranged from 9 to 26 percent (WHO, 2014b). The WHO attributes this relatively low 
percentage to the fact that febrile children are not brought in for care. According to the same report, 
ACTs have at least been replacing other antimalarial drugs across the board (both public and private 
sectors), and that the increased use of RDTs could ensure that ACTs are delivered only to those who 
actually have malaria. 
 Prompt and effective malaria treatment is a key component of the global strategy to reduce the 
burden of the disease (RBM, 2005). One reason for the low usage of antimalarial medication in the 
treatment of young children in sub-Saharan Arfica could simply be the misinterpretation of the main 
symptom of malaria, which is fever, a disease that has a variety of etiologies. Hence, without microscopy 
or other diagnostic tests, febrile children’s parents and guardians can fail to appreciate the gravity of 
the underlying cause and dismiss fever as the result of some other—perhaps less fatal—disease, such 
as the common cold. Except perhaps among the most uneducated subpopulation in the most isoalted 
regions, it would be difficult, however, to find mothers who are unfamiliar with malaria in West Africa.
 Even if children’s guardians know that a fever episode is likely caused by malaria, they used to 
abstain from administering antimalarial drugs (McCombie, 1996). More recent evidence (Adhvaryu, 
2014) note that overtreatment is more common. The recommendation by both national and 
international guidelines prevailing during the period of study, however, state that children presenting 
with fever should be presumed to have malaria, and that an antimalarial treatment cycle should 
immediately be started (WHO, 2012). Moreover, of those who decide to give their children anitmalarial 
drugs, many rely on ineffective medicine such as CQ.5 
 Although some guardians bring their febrile children to health facilities instead of self-
diagnosing and self-medicating, this is still not a guarantee that appropriate treatment will be provided, 
as shown by several regional case studies (e.g., Onwujekwe et al., 2009). These studies suggest that there 
                                                        





exists a substantial degree of heterogeneity in the quality of malaria treatment across different types of 
health-care providers (e.g., public versus private health facilities). Consequently, there should be an 
emphasis on the importance of the guardian’s decision on whether and where to seek advice for the 
treatment of febrile young children. This sheds light on understanding the observed low levels of 
(effective) antimalarial drug use (e.g., Smith et al., 2010). 
 Despite this compelling set of facts—the combination of high mortality and morbidity, drug-
resistant parasites, wildly varying quality of care—malaria, an entirely preventable and curable (with 
relatively cheap drugs) disease, remains poorly managed even by trained health professionals in 
P. falciparum-endemic countries in Africa (Brugha and Zwi, 1998; Ofori-Adjei and Arhinful, 1996; 
Williams and Jones, 2004). Clinical guidelines are under constant review (which typically can be 
considered a good thing, except that keeping guidelines in flux may make it more difficult for health 
practitioners to comply with them), the global fund to make drugs more economically accessible—
Affordable Medicines Facility-malaria (AMFm)—has been rolled back (Cohen et al., 2015), and 
underwhelming compliance with guidelines have negative consequences in the short run (e.g., the 
burden of the disease on those who are infected) but also in the long run (when multi-drug-resistant 
parasites spread even further). 
4. DATA AND STUDY POPULATION 
The data for the analysis come from the Demographic and Health Surveys (DHS) conducted for eight 
selected West sub-Saharan African countries, namely Benin, Burkina Faso, Ghana, Guinea, Liberia, Mali, 
Niger, and Nigeria. Further details about the DHS are available from the Measure DHS website at 
http://measuredhs.com. The DHS are nationally representative, consisting of three core questionnaires: 
the women’s, the men’s, and the household questionnaire. Sociodemographic characteristics are 
collected for purposes of, among others, assisting policymakers in these countries to implement 
instruments to improve public health. 
 We use one wave for Benin (2006), Burkina Faso (2003), Guinea (2005), Liberia (2006‒2007), 




2008). Since the focus of the paper is on the compliance of the provider with the treatment guidelines 
for malaria, we restrict the sample only to those children who exhibited fever within the last two weeks 
(according to the mother). The final pooled estimation sample consists of child-level data for 19,267 
children, of which 18,069 lie within the so-called “common support” (for details, see Sec. 4). 
 The outcome variables are (1) the probability of receiving antimalarial drugs, (2) the 
probability of receiving “good” antimalarial drugs, (3) the probability of receiving only CQ, and (4) the 
probability of having fever at the time of the interview. Good antimalarial drugs, which are essentially 
combination therapies of different antimalarial drugs (typically based on artemisinin), are the 
recommended first-line treatment for uncomplicated P. falciparum malaria according to national 
guidelines at the time of the interviews (see Table A3 in the Appendix). ACTs have been shown to be 
effective treatments for malaria in the presence of CQ resistance, which is the case in the eight countries 
examined in this paper (Figure 1). We exclude the year 2003 from the analysis of good antimalarial drug 
administration because national guidelines in respective countries (Burkina Faso, Ghana, and Nigeria) 
recommended CQ as first-line treatment. Otherwise, the definition of what constitutes “good 
antimalarial” always means that compliance with prevailing guidelines is good even if the guidelines 
require the use of CQ. 
 Following the definition of Filmer (2005), our health-service-provider indicators are for 
(1) going to a public hospital, (2) going to a public health facility which is not a hospital, (3) going to a 
private hospital, (4) going to a private health facility which is not a hospital, (5) going to a pharmacy or 
a shop, (6) going to a traditional healer, or (7) “self-medicating” (i.e., no advice is sought by the 
guardian). These constitute all the potential providers available to the guardian, including self-
medication or no treatment. We remove observations where the child was in contact with more than 
one treatment provider (about 2 percent of the sample). This is not likely to be problematic given the 
small number, although one could imagine that those children who have had contact with more than 
one provider did so because the first one was unsuccessful, implying either that these are worse cases 




5. ESTIMATION AND RESULTS 
5.1. ESTIMATION APPROACH 
We estimate linear probability models (LPM) for four different binary outcome variables using a set of 
five provider indicators (with self-treatment as the reference category) and further control variables as 
regressors. The LPM, despite allowing for predicted probabilities outside the unit interval, remains the 
best linear predictor and, in practice, does well as an estimator for marginal effects (Angrist and Pischke, 
2009): “If the main purpose of estimating a binary response model is to approximate the partial effects 
of the explanatory variables, averaged across the distribution of [the explanatory variables], then the 
LPM often does a very good job.” (Wooldridge, 2010, p. 563) Although the LPM also introduces het-
eroskedasticity by construction, the statistical inference presented below is robust to heteroskedastic-
ity. Nonetheless, our estimates of marginal effects obtained via the LPM do not vary substantially from 
those reported by nonlinear estimators (viz. probit and logit). 
 The estimated coefficients of the provider indicator variables yield the difference (in the proba-
bility of a positive outcome in the dependent variable) between the respective health-care providers 
and self-treatment or self-medication conditional on the covariates. Quality differences between two 
health-care providers are reflected in differences between the respective coefficients of the various pro-
viders. Wald tests are used to assess whether both coefficients significantly differ from each other. 
 The basic LPM we use in the analysis below takes the following form: 
𝑦𝑖𝑗𝑡 = 𝛽0 + 𝛃𝟏
′ 𝐏𝑖𝑗𝑡 + 𝛃𝟐
′ 𝐗𝑖𝑗𝑡 + 𝜖𝑖𝑗𝑡 , 
where the left-hand side represents a binary outcome variable, 𝑦𝑖𝑗𝑡  for child 𝑖 in country 𝑗 at time 𝑡. The 
vector of provider choices is contained in 𝐏𝑖𝑗𝑡  and other control variables are in the vector 𝐗𝑖𝑗𝑡 (which 
includes country-specific region and time (year–month combination) fixed effects, which are intended 




other independent variables). The variables contained in the vector 𝐗𝑖𝑗𝑡 increase incrementally as de-
scribed below to show the robustness of the estimated coefficients to the inclusion of socioeconomic 
well-being and environmental characteristics. The standard errors are robust to heteroskedasticity. 
 The four outcome variables are usage indicators for any, effective, and ineffective (CQ) antima-
larial drugs, as well as an indicator for the child having a fever at the time of interview. The reported 
drug use is construed to measure the drug pressure in the community (Flegg et al., 2013). We condition 
the estimations for the effective and ineffective antimalarial drug variables on children who have taken 
any antimalarial drug. This completes our construction of quality (based on drug use) because antima-
larial-drug in-take alone does not necessarily indicate better quality. While the first three indicators 
measure the appropriateness of the treatment, the fever regressions are informative about the ultimate 
effectiveness of the provider. 
 Besides the risk of being entirely ineffective, antimalarial treatment may be inappropriate if the 
child’s illness is, in reality, not due to malaria. In order to prevent parasite resistance to antimalarial 
drugs, their use should be restricted to presumed and actual malaria cases.6 This holds strongly for pro-
viders that are able to use rapid antigen tests, microscopy, serology, or some other diagnostic procedure. 
In cases where a provider advises antimalarial drug use (irrespective of whether the diagnostic test 
returned a positive result or the diagnosis was presumptive), the choice of treatment must nevertheless 
be an effective antimalarial drug (i.e., combination therapy). There is no reason to exclusively adminis-
ter CQ due to its well-known and widespread ineffectiveness against the dominant malaria parasite in 
this region. 
 The central problem for our econometric analysis is to accurately determine the expected coun-
terfactual outcome for febrile children in treatment at a certain health-care provider. The LPM allows 
                                                        
6 However, if much of the fever cases are not due to P. falciparum malaria, the presumptive treatment regime will 
lead to over-treatment, which has been shown to be harmful to both the recipient of the drug and to society in 
general, as it could lead to a slower adoption of the appropriate therapeutic choice (Adhvaryu, 2014; Cohen et al., 
2015). Although these phenomena are interesting and important, the current manuscript’s objective is to measure 
the compliance rate of different health providers with the national guidelines. Whether the guidelines themselves 





us to base the estimation of the counterfactual state on a large set of individual characteristics, environ-
mental factors, region, and time of the interview. Nevertheless, there are a number of things that remain 
unobserved, such as the severity of illness, the cost of treatment (including the distance to the provider, 
which has been shown to significantly impact the likelihood of seeking treatment (Williams and Jones, 
2004, and the references cited in Table 6 of their paper), and other determinants of health-services de-
mand. At least with the severity of illness, we are able to use variables such as the use of bed nets and 
access to safe water as proxies for the likelihood of the fever being due to malaria (e.g., bed nets reduce 
mosquito bites). We acknowledge, however, that these measures are imperfect, and they are in any case 
insufficient to address the other omitted variables that may cause estimation issues. 
 By employing many covariates, we run the risk of projecting into regions where there are no 
data points. To prevent this, we restrict our analysis to the “common support”, i.e., we ensure that, for 
each treated febrile child, there is a comparable child in the self-medication category, at least in terms 
of observable characteristics. To determine the common support, we first calculate the minimum and 
maximum predicted probabilities of being in the self-medication category for all observations. We use a 
multinomial logit model to estimate the likelihoods to fall into each of the categories (self-medication, 
traditional healer, pharmacy/shop, private hospital, other private, public hospital, or other public) 
based on control variables (but without the region and year indicators to introduce some coarseness 
and consequently increase the area of overlap). The parameter estimates are then used to calculate the 
predicted probability of being in the self-medication category for each observation. Figure 2 illustrates 
the distribution of the predicted probabilities of being in the self-medication category by each health-
care provider. 
 We then trim the sample by excluding observations that have predicted probabilities that are 
either higher than the maximum predicted probability of any of the categories or lower than the mini-
mum predicted probability of any of the categories. Restricting the estimation sample to the common 
support resulted in the exclusion of 1,198 observations (about 6 percent of the original sample). Note 
that trimming the sample implies that the resulting estimates are consistent only for observations that 




different provider choices. Nevertheless, none of our empirical claims are sensitive to the inclusion of 
observations outside the common support. 
5.2. DESCRIPTIVE STATISTICS 
The means of the outcome and provider-choice variables by country are presented in Table 1. For four 
out of the eight countries in the sample (Burkina Faso, Benin, Ghana, and Liberia), more than 50 percent 
of febrile children are treated with antimalarial drugs. While Benin ranks high in terms of antimalarial 
drug provision, it is among the worst (together with Nigeria) performers with respect to the provision 
of good antimalarial drugs, conditional on providing any antimalarial drug at all. In the sample, only 
35.9 percent of Mali’s children with a fever episode within the last two weeks received any antimalarial 
drug. Worryingly, even though the region is widely acknowledged to have CQ-resistant parasites, 
nontrivial shares of febrile children received the ineffective treatment (e.g., almost half the febrile 
children in Burkina Faso are treated only with CQ although of course CQ was the prescribed first-line 
treatment in Burkina Faso at that time, together with Ghana and Nigeria in 2003 even in the presence 
of CQ-resistant parasites). Fever abatement is highest in Niger, with about 80 percent of the children 
presenting with fever over the last two weeks no longer having fever at the time of the interview; Nigeria 
is the worst performer, with a “cure rate” of only 65 percent 
 In terms of provider choice, apart from Benin and Mali, going to a traditional healer seems to be 
a marginal phenomenon. Typically, a large share of the febrile children in this region goes to some public 
health facility which is not a hospital for treatment, with the only exception being Ghana, where most 
are taken to either a public hospital or a pharmaceutical shop.7 However, larger shares are in fact being 
self-medicated or not receiving treatment at all, with the sole exception of Liberia. Once again, this is 
troubling in a region where CQ-resistant malaria is prevalent, especially since good antimalarial drugs 
are typically not available at home (see Table A4 in the Appendix), which is probably a good thing for 
various other reasons. 
                                                        





5.3. MAIN RESULTS 
Regression results for all outcomes and three different model specifications are displayed in Table 2. In 
the basic-model specification (Column 1), we control for child-related variables, mother-related varia-
bles, household size, region fixed effects, and time fixed effects. The fixed effects partly capture the ef-
fects of antimalarial drug availability and health-care costs, since institutional factors vary considerably 
across regions and time (see Table A3 in the Appendix). The extended-model specification (Column 2) 
additionally controls for wealth and income at the household level via proxy variables. Finally, we sup-
plement the extended model with variables on environmental factors to arrive at the full-model specifi-
cation (Column 3). By gradually including income and environmental factors, such as access to safe wa-
ter and bed net usage at night time, we aim to establish the robustness of our results with respect to 
accounting for the ability to pay for health services and antimalarial drugs, as well as for the likelihood 
that the child’s fever episode is due to malaria. Since the malaria parasite is carried by mosquitoes which 
lay their larvae in stagnant water, we assume that a lack of safe water and sanitation is positively asso-
ciated with the likelihood of malaria. Bed-net use also reduces exposure to the malaria vector. 
 We discuss the separate regressions by outcome variables in turn. First, concerning the proba-
bility of using any antimalarial medication, we observe for all three model specifications significantly 
positive coefficients for public and private hospitals, other public and private facilities, and (pharma-
ceutical) shops.8 Under the full-model specification, the effect is largest for other public facilities 
(41.91 percentage points), followed by public and private hospitals with an increased likelihood to pre-
scribe antimalarial treatment of around 35 percentage points, compared to the self-medication cate-
gory. While other private facilities and (pharmaceutical) shops are also positively and significantly as-
sociated with increased antimalarial drug use relative to self-medication, we find no difference in anti-
malarial drug usage rates between children who were brought to a traditional healer and children who 
were self-medicated. 
                                                        
8 For the other outcome variables, the results are also robust across model specifications (Table 2). Henceforth, 
we focus on the results from the full-model specification. Table A2 in the Appendix presents the estimated 




 Furthermore, pairwise comparisons between traditional healers and other health-care provid-
ers show that traditional healers are significantly less likely to advise the use of antimalarial drugs. Alt-
hough Leonard (2003) shows that traditional healers may provide more effort in health care (and re-
quire more effort from their patients) because of the nature of contracting between healer and patient, 
it does not seem to translate to a higher likelihood of receiving antimalarial drugs. We find no significant 
differential between seeking advice at a public or a private hospital on the likelihood of using antima-
larial drugs. However, compared to seeking advice at other public facilities, visits to other private facil-
ities significantly decrease the likelihood to use antimalarial medication by 13.74 percentage points (𝑝-
value = 0.000). On the other hand, patients of other private facilities are 11.72 percentage points (𝑝-
value = 0.006) more likely to receive antimalarial medicine than febrile children whose parents sought 
advice at (pharmaceutical) shops. 
 With respect to receiving good antimalarial treatment (conditional on having received any anti-
malarial drug), we only observe statistically significant coefficients for public hospitals and other public 
facilities. Children advised by public hospitals have the greatest chance of receiving effective antimalar-
ial drugs. Compared to self-medication, seeking advice at a public hospital [other public facility] is asso-
ciated with an increased probability of taking an effective antimalarial drug by 4.89 [3.36] percentage 
points. At the 10-percent level of significance, the coefficients of public hospitals and other public facil-
ities are significantly larger than the coefficients of the other health-care providers. A possible explana-
tion is that, for Liberia and Nigeria (2008), good antimalarial drugs are free of charge in the public sector 
(Table A3 in the Appendix), while in the private sector, they are not. There is no significant difference 
between the two public providers. 
 As to the probability of taking CQ (conditional on having received any antimalarial drug), we 
find significant negative relationships for public and private hospitals, other public facilities, and (phar-
maceutical) shops. The associated probability of taking CQ is lower by 8.12, 8.04, 6.91, and 6.39 percent-
age points, respectively. These coefficients do not differ from each other in terms of statistical signifi-
cance. Seeking advice of traditional healers and of “other private facility” is not associated with the type 




 Finally, the fever regression results yield that—except for traditional healers—all health-care 
providers are associated with an increased likelihood of relieving fever symptoms as compared to self-
medication. Again, this points to the inefficacy of traditional healers in the context of malaria manage-
ment. The estimated coefficients range from 3.26 (other public facility) to 8.87 (other private facility) 
percentage points. Other private facilities, public hospitals, and (pharmaceutical) shops have, in abso-
lute terms, significantly larger coefficients than traditional healers (at the 10 percent level). 
5.4. SOCIOECONOMIC GRADIENT IN TREATMENT QUALITY 
To assess socioeconomic differences, we run separate regressions for each of the five wealth index 
groups (“poorest”, “poorer”, “middle”, “richer”, and “richest”) as defined by the DHS. The results are 
presented in Table 3. The distribution of wealth within a particular country can be different from 
another country in our sample, but country fixed effects are included in the regression analysis to 
capture these differences. Across wealth quintiles, we find substantial differences in the likelihood of 
receiving any antimalarial drug and in the likelihood of resolving fever for various health-care providers. 
In contrast, we find no such heterogeneity with respect to the type (effective vs. ineffective) of 
antimalarial treatment conditional on any antimalarial treatment. 
 The equality-of-coefficients test indicates that, for all providers (including traditional healers), 
significant differences exist across wealth quintiles for the antimalarial drug outcome. This holds only 
for private hospitals in the fever regressions. It must be noted, though, that the sample sizes of each 
wealth quintile is much smaller for the “good antimalarial” and “chloroquine only” regressions because 
of the conditioning on the receipt of any antimalarial drug and the lack of data for some countries. 
 For the antimalarial drug outcome variable, the coefficients of all types of health-care providers 
(except for the traditional-healer category, where the difference is not statistically significant) are lower 
among the richer and richest when compared to the poorer and poorest. In terms of the regression for 
the likelihood of having a fever at the time of the survey, we also find significant differences in the 




(both at the 10-percent significane level), and other private facilities. The larger associations, in absolute 
terms, are observed in the poorest wealth quintile. 
 We explain these socioeconomic differences by a differential in both outcomes across wealth 
quintiles among children who did not seek any advice (the reference group). The richest people may, 
for instance, be well informed about antimalarial treatments and have reserves of antimalarial drugs at 
home since rapid treatment of this disease is predictive of eventual success of treatment. In line with 
this, we observe a differential (20 and ‒6 percentage points) in the antimalarial usage rate and the 
chance to remain febrile between the richest and the poorest quintile (not displayed). 
6. NATIONAL MALARIA CONTROL STRATEGIES 
6.1 DIFFERENCES ACROSS COUNTRIES 
There is some variation in malaria-control policies across West sub-Saharan African countries. 
Differences prevail concerning the type of first-line antimalarial treatment although all post-2003 
policies recommend ACT. Further differences include costs of (public) health care and availability of 
antimalarial drugs. This section aims to shed light on the general importance of malaria-control policies 
for the quality of provided care by relating the treatment that febrile children receive at different health-
care providers with facets of national policies. That is, we analyze whether the benefit of visiting a 
certain health-care provider is related to the various institutional aspects of malaria control. The 
country-by-country estimation results are provided in Table 4 and Table 5. 
 It is evident that more formal providers (those other than traditional healers) are much more 
likely to provide antimalarial drugs to febrile children across all countries. However, within each 
country, there is some variation in how much more likely antimalarial drugs will be provided relative to 
self-medication. For example, in Burkina Faso, going to a public hospital is associated with a 20-percent 
increase in the probability of receiving an antimalarial drug compared to self-medication, but this same 
effect is estimated to be 60 percent in Liberia. Concerning the type of antimalarial drug, the public and 




treatment (Table 4, lower panel). In this country, public and private hospitals, other public facilties, and 
(pharmaceutical) shops all exhibit a significantly positive coefficient.  
 Heterogeneity across countries is more pronounced with regard to CQ-only treatment (Table 5, 
upper panel). A lower likelihood of receiving only CQ compared to self-medication is found in the public 
sector in Ghana, Guinea (public hospitals in both countries), Burkina Faso, Mali, and Niger (other public 
facilities in the three countries). In Benin, Liberia, and Nigeria, public sector patients are just as likely to 
take CQ as self-medicating children. In enin and Liberia, this may be explained by relatively low overall 
CQ utilization rates (Tabel 1). In Nigeria, however, CQ use is very common, which is could indicate the 
low quality of public services but more likely because CQ was the first-line treatment in 2003. 
 The effectiveness of health-care providers in terms of fever relief is highest in Liberia (Table 5, 
lower panel). All individual health-care provider coefficients are significant and amount to more than 
20 percent. Hence, irrespective of the type of provider (including, interestingly, tradtional healers), 
seeking advice for a febrile child at any health-care provider is strongly recommendable in Liberia. 
Notably, Liberia has free testing and free ACT in the public sector. In the other countries, the difference 
in fever relief success across health-care providers is less pronounced. 
6.2 CHANGE IN NATIONAL POLICIES OVER TIME 
For Ghana and Nigeria, we are able to use information from two waves of the DHS (2003 and 2008 for 
both countries). The goal of this exercise is to determine whether there were differences in the 
effectiveness of the different providers between the two time periods and whether these differences 
over time vary across the two countries. The latter will give an indication regarding the impact of 
different malaria-control policies because both countries implemented reforms of their national 
guidelines between 2003 and 2008. These two countries represent interesting cases because both had 
similar policies in place with CQ as first-line treatment, presumptive antialaria medication, and fee for 
services in 2003 but malaria control reforms—except of the introduction of ACT as first-line treatment 





 Ghana demonstrated an improvement in treatment quality as compared to self-medication 
while Nigeria presents a rather mixed case. Considering, for instance, the likelihood of receiving 
antimalarial drugs, the difference between self-treatment and all health care providers except 
traditional healers increased substantially between the years 2003 and 2008 for Ghana. Private 
hospitals (from 11.19 to 51.08 percentage points) and pharmaceutical shops (from 16.82 to 39.33 
percentage points) represent the most dramatic increases. In contrast, the corresponding estimates for 
Nigeria declined in each case. The likelihood for traditional healers to provide antimalarial drugs 
remains to be statistically indistinguishable from self-treatment for both countries over time. 
 Quality improvements of public and private hospitals as well as traditional healers can be 
observed with respect to the provision of CQ-only for Ghana. Ghana’s achievements may be explained 
by the nation’s effort to address CQ-resistant malaria. In fact, Ghana replaced its own Anti-Malaria Drug 
Policy with one that was more in line with the WHO guidelines. The latter not only required presumptive 
malaria treatment but also encouraged the adoption of artesunate with amodiaquine, a type of ACT. 
Since 2002, taxes were waived on the importation of insecticide-treated bed nets in the country. Its 
distribution to poorer areas of the country, in particular to pregnant women and children under five, 
was also subsidized by the state. According to the DHS final report on Ghana for 2008, “Implementation 
of the new treatment policy began in the last quarter of 2005 with countrywide training of health-care 
providers in both private and public sectors…The [Ghana Health Service] strongly advised caregivers of 
young children with signs and symptoms of malaria to access treatment at the nearest health facility.” 
 Although a similar program was introduced in Nigeria as well (also in response to the rise of the 
CQ-resistant parasite), the ACT treatment in Nigeria was based on artemether with lumefantrine, as 
opposed to the treatment encouraged in Ghana (artesunate with amodiaquine). Although the Nigerian 
government has undertaken steps as well to ensure increased access to ACT, it seems that their efforts 




7. DISCUSSION AND CONCLUSION 
Our main findings are the following. First, compared to self-treatment, children who seek treatment at 
public and private hospitals, other public and private facilities, and (pharmaceutical) shops have a 
significantly higher likelihood to take any antimalarial drug at all. Going to a traditional healer is no 
different from self-medication. The largest correlation is found for non-hospital (“other”) public 
facilities: government-run health centers, government field worker, and other public-sector health 
points are associated with an increased likelihood of antimalarial drug use by 89 percent. This is an 
important result since our data show that guardians of children with fever who seek advice are most 
likely to visit other public facilities. 
 At the same time, it should be noted that these treatment practices may not necessarily translate 
to other groups (i.e., those who are not children below five years of age). This is especially true for 
complicated malaria, such as those experienced by pregnant women, and malaria experienced by older 
children. The prevalence of malaria is highly age dependent, since children below five years are more 
likely to have malaria conditional on having a fever than children who are older simply because they 
have developed immunity to P. falciparum (unlike P. vivax, which, although less severe and associated 
with less complications, can recur). 
 With respect to receiving good antimalarial treatment (conditional on having received any anti-
malarial drug), we only observe significant associations for public hospitals and other public facilities. 
This may be explained by national and international efforts to make ACTs available on a large scale 
through public channels. As to the probability of taking only CQ conditional on antimalarial treatment, 
we find significant correlations for public and private hospitals, other public facilities, and (pharmaceu-
tical) shops. While other private facilities such as private doctors and private maternity homes do not 
perform any better than self-treatment in terms of good antimalarial drug and CQ-only use, they are 




 We have exhausted all avenues this particular dataset allows to rule out confounding factors. 
First, we control for a wide range of individual, household, and environmental factors. Second, we car-
ried out several robustness tests such as the gradual incorporation of proxy variables for income and 
the likelihood that the fever episode is due to malaria into our econometric model. Nevertheless, we do 
not directly observe whether a child actually has malaria. If malaria is associated with a higher chance 
of both seeking advice at, for instance, public health centers and (effective) antimalarial medication, 
effect estimates can be biased.9 Indeed, we do not have information on differential treatment practices 
for laboratory- or RDT-confirmed malaria cases. Given these considerations, the results should certainly 
be interpreted with caution, although there are a number of reasons why we are less concerned about 
selection while acknowledging its likely presence. 
 First, the presumptive treatment regimen makes these associations irrelevant because all febrile 
children should have received antimalarial medication in any case. The fundamental issue is the ability 
of health-care providers to comply with national and international guidelines, which may change in 
response to the declining prevalence of P. falciparum malaria in sub-Saharan Africa. When these 
guidelines change, high-quality providers can be expected to rapidly comply while low-quality providers 
may never do. Second, the inclusion of malaria proxy variables such as indicators for access to safe water 
and bed-net usage at night time only marginally changed the provider coefficients. If differences in the 
likelihood of being exposed to malaria were the main factors that influenced the provider choice, then 
we expect larger differences between estimates from the model with and without these proxy variables 
for malaria exposure. Third, we find similar quality differences across health-care providers when we 
restrict the sample to children who received any antimalarial medication and look at the type of 
antimalarial drug used. By administering antimalarial drugs to these children,  providers make their 
assessment of a malaria case explicit, irrespectively of whether it is based on a diagnostic test result or 
presumptive treatment. Administering first-line antimalarial drugs is then a definite signal of good 
quality (and CQ-only use, conversely, a signal of bad quality). 
                                                        




 Cross-country comparisons of the estimated health-care provider coefficients on antimalarial 
drug use and the fever outcome variable reveal substantial heterogeneity in the quality of care across 
countries. Variation across insititutional frameworks allows us to assess whether, conditional on 
regional fixed effects within a country, unobserved price elasticities and drug availability influence our 
results. We do not find any strong indication of this in the data. For instance, Liberia and Nigeria (2008) 
are two countries where both advice and antimalarial drugs are free of charge in the public sector. In 
Liberia, public facilities perform above average in terms of treatment quality (except good antimalarial 
drug use). In Nigeria, they achieve average results. If public providers actually exert no influence on 
antimalarial drug use and our results are mainly driven by price elasticities, we should not find 
considerable differences for public sector entities in these countries because the absence of health-care 
fees eliminates the effect of the price of health services. In contrast, if drug availability is an important 
unobserved factor, we should observe higher—rather than lower—coefficients for public providers in 
Nigeria (where drug availability is much better). 
 Our results indicate that private-sector treatment (including pharmaceutical shops) is not any 
better than self-medication in terms of first-line compliance. For these providers, we know that they 
have a higher likelihood of prescribing some antimalarial drug but it is not exclusively CQ. However, it 
is also not a combination therapy. Therefore, it must be the case that these providers are prescribing 
antimalarial drugs as monotherapies or not according to the national guidelines. This has profound 
negative implications for the development of drug-resistant parasites. The WHO (2006b) recommends 
that artemisinin should not be allowed to be marketed as monotherapies precisely for this reason. 
 It is obvious that a variety of antimalarial drugs are currently being provided in the market, 
which also has implications for the development of drug-resistant parasites. There is some evidence, 
based on the experience of Malawi, that a reduction in drug pressure could increase the susceptibility 
of P. falciparum to older-generation drugs (Flegg et al., 2013). Note that Malawi transitioned from CQ to 
SP in 1993 and stayed with that first-line treatment for uncomplicated malaria until 2007, when it fol-
lowed most other countries by adopting ACTs as the first-line drug. For more than a decade, CQ was not 




emerged (Frosch et al., 2011). If nations which have adopted ACT as the first-line drug manage to com-
pletely remove CQ from the market, there may be an opportunity in the future to reintroduce it as the 
CQ-susceptible variant parasite returns, implying that drugs may be cycled in a regime of changing clin-
ical guidelines. 
 This points to the need for programs to improve private sector access to arteminisin-based 
combination therapies (ACT). The Affordable Medicines Facility-malaria (AMFm) managed by the 
Global Fund to Fight AIDS, Tuberculosis and Malaria, for instance, represents an effective way to close 
the ACT-availability gap between the public and private sectors. Based on the initial idea of Arrow 
(2004), AMFm works by negotiating with drug manufacturers to reduce the price of ACT, and to require 
sales-price parity between the public and private sectors. As Cohen et al. (2015) note, “fewer than 
15 percent of African children with malaria were treated with ACTs.” Tougher et al. (2012) show in 
several pilot studies that there were large increases in ACT availability and market share driven mainly 
by changes in the private for-profit sector. This is an important initiative because “CQ and SP are up to 
25 times less expensive than an ACT” (Flegg et al, 2013:863). Even traditional healers “command fees 
exceeding the average treatment cost at most modern practitioners” (Leonard, 2003). 
 However, there is an acknowledged tradeoff when choosing to subsidize ACTs especially when 
clinical confirmation of the presence of malaria is not that common. Since ACTs may be administered to 
patients who do not have malaria, the scope for heterogeneous returns is much larger. Demand for the 
drug may therefore bifurcate: those with higher returns will increase their demand for the treatment 
while those with lower returns will demand less (Cohen et al., 2015). For those receiving the treatment 
even without having malaria, their returns are low, and this could negatively impact on the adoption of 
the new therapies (Adhvaryu, 2014). Ultimately, we could end up in a situation of overtreatment under 
a regime of presumptive treatment, where the recovery of those without malaria is delayed, resources 
allocated for actual malaria are wasted, and drug-resistant parasites are the norm (Cohen et al., 2015). 
 We are concerned that such instruments like AMFm fail to reach the poorest unless they come 




(2005) finds the lowest advice-seeking rates among the poorest. We observe that, within the self-
treatment group, the poorest are also those who have the lowest likelihood to take any antimalarial drug 
(and, conditional on taking such drugs, they have the highest likelihood to take the ineffective ones). We 
therefore recommend complementing national and international efforts directed towards the 
availability of ACTs with measures to improve health-service use among the poor. 
 In addition, the shift to a “test and treat” regime should be facilitated by making RDTs widely 
available coupled with appropriate training for their use. Cohen et al. (2015) show that subsidizing 
RDTs by up to 85 percent or more and making them more available “doubles the rate at which illnesses 
are tested for malaria.” While presumptive treatment was useful when malaria was highly prevalent, 
the disease is now in decline, and the balance is shifting to overtreatment in certain situations. If 
confirmatory tests can be made more available, advocating for a presumptive-treatment regime will 
become a less tenable position to take. 
 As possible policy instruments, demand-side and supply-side performance-based incentive 
schemes have been suggested in the literature (e.g., Eichler et al., 2009). Rewarding the poorest families 
for seeking care for their febrile children and rewarding providers for the use of rapid diagnostic tests 
and (conditional on a positive test result) to administer ACTs are obvious candidates for such 
interventions. Performance-based provider incentives would have the attractive feature of encouraging 
higher treatment-seeking rates. There are several ways a provider may be able to increase the use of its 
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MEANS OF OUTCOME AND TREATMENT VARIABLES BY COUNTRY 
 
Burkina Faso Benin Ghana Guinea Liberia Mali Nigeria Niger 
Outcome         
Antimalarial 0.5345 0.5734 0.5765 0.4361 0.5731 0.3588 0.3868 0.3638 
Good antimalarial — 0.0080 0.4811 — 0.1468 — 0.0755 — 
Chloroquine only 0.4881 0.1854 0.1982 0.2303 0.1343 0.3756 0.3398 0.4513 
Has fever now 0.2672 0.2430 0.3041 0.3219 0.2801 0.3461 0.3500 0.1929 
Provider         
Public hospital 0.0187 0.0290 0.2199 0.0299 0.1169 0.0139 0.1091 0.0215 
Other public facility 0.3051 0.2316 0.1778 0.2695 0.2801 0.2579 0.1448 0.2950 
Private hospital 0.0041 0.0420 0.0593 0.0087 0.1219 0.0111 0.0587 0.0128 
Other private facility 0.0108 0.0572 0.0155 0.0225 0.0634 0.0227 0.1649 0.1344 
Pharmacy/shop 0.0823 0.1123 0.2053 0.1703 0.1361 0.0377 0.2228 0.1503 
Traditional healer 0.0575 0.1728 0.0455 0.0892 0.0727 0.2085 0.0308 0.0282 
Self-medication 0.5214 0.3550 0.2766 0.4099 0.2088 0.4481 0.2689 0.3576 
Observations 3147 3687 1164 1603 1403 1803 4511 1949 
NOTES: In calculating the share of children who took good antimalarial drugs and chloroquine, the observations are restricted to those who have 
taken any antimalarial drug. Hence, the numbers of observations above do not apply for the rows “Good antimalarial” and “Chloroquine only”. 
We have no information available on whether good antimalarial drugs were provided in Burkina Faso, Guinea, Mali, and Niger. For Ghana and 
Nigeria, good antimalarial drug refers to the year 2008 only. 







LINEAR PROBABILITY MODEL ESTIMATION RESULTS FOR DIFFERENCES IN THE TREATMENT PRACTICE ACROSS HEALTH-CARE PROVIDERS  
 Basic model Extended model Full model 
Any antimalarial    
Public hospital 0.3573*** 0.3505*** 0.3499*** 
 (0.0156) (0.0157) (0.0157) 
Other public facility 0.4273*** 0.4200*** 0.4191*** 
 (0.0088) (0.0089) (0.0089) 
Private hospital 0.3541*** 0.3483*** 0.3474*** 
 (0.0186) (0.0187) (0.0187) 
Other private facility 0.2866*** 0.2820*** 0.2817*** 
 (0.0145) (0.0145) (0.0145) 
Pharmacy/shop 0.1679*** 0.1654*** 0.1645*** 
 (0.0114) (0.0114) (0.0114) 
Traditional healer 0.0095 0.0081 0.0079 
 (0.0128) (0.0128) (0.0127) 
Observations 18069 18069 18069 
Good antimalarial    
Public hospital 0.0499** 0.0485** 0.0489** 
 (0.0185) (0.0185) (0.0185) 
Other public facility 0.0335*** 0.0335*** 0.0336*** 
 (0.0092) (0.0092) (0.0092) 
Private hospital 0.0062 0.0043 0.0054 
 (0.0161) (0.0160) (0.0160) 
Other private facility 0.0046 0.0043 0.0038 
 (0.0109) (0.0109) (0.0109) 
Pharmacy/shop 0.0072 0.0079 0.0083 
 (0.0138) (0.0139) (0.0139) 
Traditional healer 0.0060 0.0063 0.0059 
 (0.0118) (0.0114) (0.0115) 
Observations 4305 4305 4305 
Chloroquine only    
Public hospital 0.0934*** 0.0851*** 0.0812*** 
 (0.0190) (0.0190) (0.0189) 
Other public facility 0.0751*** 0.0716*** 0.0691*** 
 (0.0133) (0.0133) (0.0133) 
Private hospital 0.0959*** 0.0833*** 0.0804*** 
 (0.0208) (0.0209) (0.0208) 
Other private facility 0.0067 0.0036 0.0013 
 (0.0206) (0.0205) (0.0205) 
Pharmacy/shop 0.0676*** 0.0677*** 0.0639*** 
 (0.0175) (0.0175) (0.0174) 
Traditional healer 0.0106 0.0121 0.0098 
 (0.0221) (0.0221) (0.0221) 
Observations 8593 8593 8593 
Has fever now    
Public hospital 0.0616*** 0.0582*** 0.0570*** 
 (0.0151) (0.0152) (0.0152) 
Other public facility 0.0349*** 0.0337*** 0.0326*** 
 (0.0091) (0.0091) (0.0091) 
Private hospital 0.0535** 0.0480** 0.0470* 
 (0.0184) (0.0185) (0.0185) 
Other private facility 0.0907*** 0.0895*** 0.0887*** 
 (0.0140) (0.0140) (0.0140) 
Pharmacy/shop 0.0481*** 0.0470*** 0.0462*** 
 (0.0110) (0.0110) (0.0110) 
Traditional healer 0.0216 0.0220 0.0218 
 (0.0129) (0.0129) (0.0129) 
Observations 18069 18069 18069 








TABLE 3: ESTIMATION RESULTS BY WEALTH INDEX 
 Poorest Poorer Middle Richer Richest 
Antimalarial      
Public hospital 0.3955*** 0.4849*** 0.3712*** 0.2973*** 0.1473*** 
 (0.0392) (0.0362) (0.0364) (0.0331) (0.0366) 
Other public facility 0.4867*** 0.4576*** 0.4132*** 0.3991*** 0.2504*** 
 (0.0198) (0.0192) (0.0189) (0.0201) (0.0260) 
Private hospital 0.4589*** 0.4272*** 0.3482*** 0.3298*** 0.1704*** 
 (0.0520) (0.0537) (0.0452) (0.0356) (0.0382) 
Other private facility 0.3109*** 0.3719*** 0.2657*** 0.2131*** 0.1451*** 
 (0.0294) (0.0303) (0.0324) (0.0349) (0.0405) 
Pharmacy/shop 0.2073*** 0.2187*** 0.1472*** 0.1335*** 0.0026 
 (0.0211) (0.0233) (0.0262) (0.0284) (0.0356) 
Traditional healer 0.0251 0.0135 0.0840** 0.0066 0.0219 
 (0.0229) (0.0254) (0.0266) (0.0349) (0.0490) 
Observations 4127 3937 3853 3563 2589 
Good antimalarial      
Public hospital 0.0497 0.0709 0.0122 0.0561 0.0798 
 (0.0650) (0.0364) (0.0379) (0.0347) (0.0494) 
Other public facility 0.0098 0.0692*** 0.0349 0.0261 0.0651* 
 (0.0206) (0.0200) (0.0214) (0.0191) (0.0304) 
Private hospital 0.0022 0.0138 0.0400 0.0099 0.0399 
 (0.0444) (0.0478) (0.0412) (0.0313) (0.0366) 
Other private facility 0.0373 0.0052 0.0178 0.0094 0.0044 
 (0.0236) (0.0252) (0.0237) (0.0260) (0.0255) 
Pharmacy/shop 0.0476 0.0632* 0.0536 0.0258 0.0021 
 (0.0281) (0.0317) (0.0375) (0.0302) (0.0321) 
Traditional healer 0.0303 0.0197 0.0156 0.0378 0.0356 
 (0.0291) (0.0239) (0.0237) (0.0237) (0.0301) 
Observations 823 909 981 972 620 
Chloroquine only      
Public hospital 0.1529** 0.0190 0.1669*** 0.0794* 0.0109 
 (0.0555) (0.0512) (0.0427) (0.0384) (0.0399) 
Other public facility 0.0600 0.0819* 0.0694* 0.0889** 0.0277 
 (0.0342) (0.0324) (0.0286) (0.0276) (0.0319) 
Private hospital 0.1132 0.0695 0.0833 0.1457*** 0.0244 
 (0.0714) (0.0644) (0.0525) (0.0365) (0.0421) 
Other private facility 0.0347 0.0765 0.0006 0.0717 0.0209 
 (0.0503) (0.0478) (0.0469) (0.0440) (0.0479) 
Pharmacy/shop 0.0595 0.0743 0.0792* 0.0916* 0.0113 
 (0.0438) (0.0409) (0.0385) (0.0364) (0.0455) 
Traditional healer 0.0471 0.0847 0.0087 0.0057 0.0214 
 (0.0491) (0.0502) (0.0494) (0.0486) (0.0584) 
Observations 1531 1689 1887 1964 1522 
Has fever now      
Public hospital 0.0811* 0.0532 0.0737* 0.0838** 0.0159 
 (0.0397) (0.0386) (0.0372) (0.0312) (0.0323) 
Other public facility 0.0525* 0.0269 0.0121 0.0243 0.0262 
 (0.0206) (0.0200) (0.0203) (0.0209) (0.0231) 
Private hospital 0.1146 0.0903 0.0752 0.0871* 0.0070 
 (0.0611) (0.0514) (0.0452) (0.0361) (0.0344) 
Other private facility 0.1324*** 0.0665* 0.0968** 0.0817* 0.0339 
 (0.0292) (0.0312) (0.0311) (0.0334) (0.0367) 
Pharmacy/shop 0.0214 0.0600* 0.0614* 0.0564* 0.0202 
 (0.0220) (0.0233) (0.0252) (0.0266) (0.0302) 
Traditional healer 0.0210 0.0006 0.0215 0.0216 0.0056 
 (0.0247) (0.0270) (0.0283) (0.0321) (0.0422) 




NOTES: Regression results are based on the full model specification. The reference category is self-medication. * significant at 5%, 
** significant at 1%, *** significant at 0.1%. Robust standard errors are in parentheses. We have no information available on 
whether good antimalarial drugs were provided in Burkina Faso, Guinea, Mali, and Niger. For Ghana and Nigeria, good 
antimalarial drug refers to the year 2008 only. 





PROVIDER DIFFERENCES BY COUNTRY (ANTIMALARIAL) 
 
Burkina Faso Benin Ghana Guinea Liberia Mali Nigeria Niger 
Antimalarial         
Public hospital 0.2077** 0.2499*** 0.3547*** 0.5685*** 0.6023*** 0.3814*** 0.3000*** 0.3004*** 
 (0.0718) (0.0466) (0.0402) (0.0645) (0.0423) (0.1148) (0.0257) (0.0813) 
Other public facility 0.3552*** 0.4088*** 0.2749*** 0.5317*** 0.4976*** 0.4229*** 0.4151*** 0.5398*** 
 (0.0207) (0.0191) (0.0422) (0.0284) (0.0348) (0.0288) (0.0224) (0.0263) 
Private hospital 0.5441*** 0.2618*** 0.2804*** 0.5640*** 0.5472*** 0.3591** 0.3494*** 0.3172** 
 (0.0433) (0.0372) (0.0697) (0.1231) (0.0456) (0.1217) (0.0324) (0.1081) 
Other private facility 0.0639 0.3752*** 0.1489 0.3366*** 0.5429*** 0.2165* 0.2607*** 0.2340*** 
 (0.1028) (0.0285) (0.1239) (0.0905) (0.0541) (0.0865) (0.0226) (0.0340) 
Pharmacy/shop 0.1461*** 0.0311 0.2343*** 0.2631*** 0.3683*** 0.1995** 0.1917*** 0.1318*** 
 (0.0364) (0.0279) (0.0417) (0.0368) (0.0446) (0.0616) (0.0193) (0.0322) 
Traditional Healer 0.1585*** 0.0113 0.0326 0.0869* 0.1266* 0.0263 0.0603 0.0708 
 (0.0363) (0.0238) (0.0698) (0.0377) (0.0520) (0.0284) (0.0317) (0.0569) 
Observations 2482 3661 1144 1438 1372 1710 4413 1849 
Good antimalarial         
Public hospital  0.0094 0.2957*  0.0302  0.0556  
  (0.0098) (0.1457)  (0.0636)  (0.0313)  
Other public facility  0.0148*** 0.3561*  0.0048  0.0326  
  (0.0044) (0.1439)  (0.0581)  (0.0238)  
Private hospital  0.0010 0.3937*  0.0714  0.0056  
  (0.0036) (0.1752)  (0.0631)  (0.0334)  
Other private facility  0.0018 0.2984  0.0729  0.0100  
  (0.0027) (0.2698)  (0.0716)  (0.0207)  
Pharmacy/shop  0.0035 0.3710*  0.1132  0.0232  
  (0.0031) (0.1449)  (0.0632)  (0.0292)  
Traditional Healer  0.0068 0.0758  0.0976  0.0313  
  (0.0069) (0.2885)  (0.0842)  (0.0278)  
Observations  2108 209  786  1202  
NOTES: Regression results are based on the full model specification. The reference category is self-medication. * significant at 5%, ** significant at 1%, *** significant at 0.1%. Robust standard errors are in parentheses. We have no information 
available on whether good antimalarial drugs were provided in Burkina Faso, Guinea, Mali, and Niger. For Ghana and Nigeria, the information on good antimalarial drugs refers to the year 2008. 





PROVIDER DIFFERENCES BY COUNTRY (CHLOROQUINE, FEVER) 
 Burkina 
Faso 
Benin Ghana Guinea Liberia Mali Nigeria Niger 
Chloroquine 
only 
        
Public hospital 0.1288 0.0401 0.1106* 
0.1424
* 















(0.0588) (0.0438) (0.0535) (0.0494) (0.0399) (0.0595) 










(0.0664) (0.0766) (0.0574) (0.0886) (0.0487) (0.1526) 
Other private 
facility 




(0.0914) (0.1107) (0.0702) (0.1259) (0.0434) (0.0716) 
Pharmacy/sho
p 
0.0142 0.0204 0.0864 
0.1194
* 




(0.0552) (0.0552) (0.0624) (0.0893) (0.0424) (0.0797) 
Traditional 
Healer 






(0.1027) (0.1148) (0.0768) (0.0690) (0.1245) (0.1196) 
Observations 1361 2108 663 648 786 628 1723 676 
Has fever now         
Public hospital 0.0052 0.0378 0.1057* 0.1168 
0.2447**
* 




(0.0417) (0.0686) (0.0481) (0.0922) (0.0261) (0.0659) 
Other public 
facility 
0.0144 0.0249 0.0598 0.0290 
0.2952**
* 




(0.0439) (0.0319) (0.0364) (0.0290) (0.0244) (0.0252) 
Private hospital 0.1215 0.0202 0.1017 0.0619 
0.2296**
* 




















(0.0799) (0.0876) (0.0544) (0.0730) (0.0242) (0.0284) 
Pharmacy/sho
p 
0.0254 0.0398 0.0494 0.0519 
0.2563**
* 

















(0.0661) (0.0463) (0.0488) (0.0299) (0.0440) (0.0558) 
Observations 2482 3661 1144 1438 1372 1710 4413 1849 
NOTES: Regression results are based on the full model specification. The reference category is self-medication. * significant at 
5%, ** significant at 1%, *** significant at 0.1%. Robust standard errors are in parentheses. 











ESTIMATION RESULTS FOR GHANA AND NIGERIA FOR 2003 AND 2008 
 Ghana Nigeria 
 2003 2008 2003 2008 
Antimalarial     
Public hospital 0.3148*** 0.4408*** 0.4260*** 0.2573*** 
 (0.0536) (0.0656) (0.0460) (0.0307) 
Other public facility 0.2298*** 0.3370*** 0.5438*** 0.3893*** 
 (0.0599) (0.0632) (0.0455) (0.0257) 
Private hospital 0.1119 0.5108*** 0.5288*** 0.3081*** 
 (0.0941) (0.1051) (0.0593) (0.0385) 
Other private facility 0.0099 0.3446* 0.3694*** 0.2398*** 
 (0.1751) (0.1435) (0.1064) (0.0238) 
Pharmacy/shop 0.1682** 0.3933*** 0.3010*** 0.1434*** 
 (0.0572) (0.0745) (0.0318) (0.0245) 
Traditional healer 0.0064 0.0224 0.0739 0.0190 
 (0.1161) (0.1005) (0.0456) (0.0449) 
Observations 664 480 1231 3182 
Good antimalarial     
Public hospital  0.2957*  0.0556 
  (0.1457)  (0.0313) 
Other public facility  0.3561*  0.0326 
  (0.1439)  (0.0238) 
Private hospital  0.3937*  0.0056 
  (0.1752)  (0.0334) 
Other private facility  0.2984  0.0100 
  (0.2698)  (0.0207) 
Pharmacy/shop  0.3710*  0.0232 
  (0.1449)  (0.0292) 
Traditional healer  0.0758  0.0313 
  (0.2885)  (0.0278) 
Observations  209  1202 
Chloroquine only     
Public hospital 0.0458 0.2404* 0.0782 0.0925 
 (0.0706) (0.0992) (0.0966) (0.0492) 
Other public facility 0.0684 0.1970 0.1153 0.0530 
 (0.0749) (0.1007) (0.0970) (0.0452) 
Private hospital 0.1178 0.2316* 0.0673 0.0772 
 (0.1202) (0.0903) (0.1121) (0.0557) 
Other private facility 0.0285 0.1583 0.0590 0.0472 
 (0.1654) (0.1190) (0.1518) (0.0463) 
Pharmacy/shop 0.0071 0.1838 0.0624 0.0466 
 (0.0685) (0.1002) (0.0903) (0.0544) 
Traditional healer 0.0441 0.2748* 0.3600 0.3090* 
 (0.1432) (0.1206) (0.3041) (0.1430) 
Observations 454 209 521 1202 
Has fever now     
Public hospital 0.1308* 0.1214 0.0703 0.0950** 
 (0.0554) (0.0677) (0.0485) (0.0312) 
Other public facility 0.0310 0.1046 0.1007* 0.0579* 
 (0.0631) (0.0656) (0.0479) (0.0281) 
Private hospital 0.1569 0.1091 0.0164 0.0768 
 (0.0931) (0.0932) (0.0584) (0.0404) 
Other private facility 0.2909* 0.1464 0.0158 0.1068*** 
 (0.1359) (0.1145) (0.0977) (0.0257) 
Pharmacy/shop 0.0895 0.0721 0.0226 0.0575* 
 (0.0574) (0.0729) (0.0368) (0.0284) 
Traditional healer 0.1734 0.2645** 0.0844 0.0294 
 (0.1047) (0.0955) (0.0700) (0.0585) 




NOTES: Regression results are based on the full model specification. The reference category is self-medication. * significant at 
5%, ** significant at 1%, *** significant at 0.1%. Robust standard errors are in parentheses. We have information available on 
good antimalarial drugs in year 2008 only. 







MAP SHOWING THE DISTRIBUTION OF MALARIA IN THE WORLD 
 
NOTE: ♦ Elevated occurrence of chloroquine- or multi-resistant malaria, ♦ Occurrence of chloroquine-
resistant malaria, ♦ No Plasmodium falciparum or chloroquine-resistance, ♦ No malaria. 






ESTIMATED PROBABILITY TO SELF-MEDICATE BY HEALTH-CARE PROVIDER CATEGORY 
 
 
 
 
 
